Agendia and Illumina recently began a multi-year partnership to advance the use of next-generation sequencing (NGS) for decentralized oncology testing.
The companies announced the partnership in a Jan. 10 press release.
“This partnership represents a major step in Agendia’s integration of NGS technologies and brings us even closer to our promise of providing crucial genomic information to physicians and their patients to guide care at every single step in a patient’s treatment journey,” Mark Straley, Agendia CEO said in the release. “We believe our current FDA-cleared, broadly reimbursed MammaPrint test provides the perfect foundation for incorporation with Illumina’s MiSeqDx platform."
Agendia provides physicians with "next-generation diagnostic and information solutions that can be used to help improve outcomes for breast cancer patients," according to the release. Illumina develops technology for large-scale genetic variation and function analysis, according to its website.
“Together, we plan to expand what is possible in breast cancer care and ensure that the essential insights that come from genomic testing are delivered to patients around the world,” Straley said.
Joydeep Goswami, chief strategy and corporate development officer of Illumina, shared his excitement about the partnership.
“We are pleased to partner with Agendia, with its deep expertise in genomic testing in breast cancer, to expand the reach of NGS-based genomic testing in cancer care,” he said. “We believe enabling in-house clinical testing will strengthen the knowledge of the healthcare network, reduce turnaround times, and ultimately better support more patients with improved guidance on care pathways.”
Illumina’s diagnostic NGS product portfolio, including the MiSeq™Dx platform, covers a range of clinical applications designed for a variety of clinical lab settings, the release stated.